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Abstract
Objective: Primary transitional cell carcinoma (TCC) of
the upper urinary tract represents 6–8% of all TCC cases.
Nephroureterectomy with removal of a bladder cuff is
the treatment of choice. The rates of TCC recurrence in
the bladder after primary upper urinary tract surgery
described in the literature range between 12.5 and
37.5%. In a retrospective analysis we examined the oc-
currence of TCC after nephroureterectomy for upper
tract TCC in patients without a previous history of blad-
der TCC at the time of surgery. Methods: Between 1990
and 2002, 29 patients underwent primary nephroureter-
ectomy for upper tract TCC. The mean age of the patients
was 69.5 years. In 5 cases upper urinary tract tumors
were multilocular, in the remaining cases unilocular in
the renal pelvis (n = 12) or the ureter (n = 12). The follow-
up was available for 29 patients with a mean follow-up of
3.37 (0.1–11.2) years. Results: 11/29 (37.9%) patients had
TCC recurrence with 9/11 patients having bladder TCC
diagnosed within 2.5 years (0.9–6.0) after nephroureter-
ectomy. 13/29 patients are alive without TCC recurrence,
3/29 patients died due to systemic TCC progression and
5/29 died of unrelated causes without evidence of TCC
recurrence. Conclusion: Our data indicate a high inci-
dence of bladder TCC after nephroureterectomy for pri-
mary upper tract TCC of up to 6 years after primary sur-
gery. Because of the high incidence of bladder TCC with-
in the first 3 years of surgery, careful follow-up is needed
over at least this period.
Copyright © 2004 S. Karger AG, Basel
Introduction
The primary diagnosis of upper urinary transitional
cell carcinoma (TCC) accounts for approximately 6–8%
of all TCCs [1]. The treatment of choice for upper tract
TCC is nephroureterectomy with the removal of a bladder
cuff. Recurrence rates after nephroureterectomy given in
the literature range from 12.5 to 38% [2–4].
In case of contraindications to nephrectomy (azote-
mia, solitary kidney, bilateral disease) renal-sparing sur-
gery is advocated [5], which includes open segmental and
endoscopic procedures. In the literature, segmental ure-
teral resection has been preferred for low-grade and low-
stage tumors [1, 5].
210 Urol Int 2004;73:209–211 Oehlschläger/Baldauf/Wiessner/Gellrich/
Hakenberg/Wirth
Charbit et al. [6] calculated a risk of bladder TCC
recurrence of approximately 9% after upper tract TCC
surgery. In patients with a previous history of bladder
TCC, a higher risk of bladder TCC recurrence up to 70%
has been reported [6, 7]. Krogh et al. [1] reported a blad-
der TCC recurrence rate of 36.4% after upper tract TCC
surgery. However, in their retrospective series, 198 pa-
tients with different and not comparable surgical tech-
niques as well as patients with concurrent as well as pre-
ceding bladder TCCs at the time of nephroureterectomy
were included.
Because of the varying recurrence rates described in
the literature, we analyzed the bladder TCC recurrence
rate after nephroureterectomy for TCC of the upper tract
in the subgroup of patients without concurrent or pre-
vious bladder TCC at the time of surgery of nephroureter-
ectomy.
Materials and Methods
Between 1990 and 2002, 29 patients (21 men and 8 women) with-
out cystoscopic evidence of concurrent bladder TCC and without a
history of previous bladder TCC underwent primary nephroureterec-
tomy. The TCC was located on the right side in 15 patients and on
the left side in 14 patients. 26 patients underwent open nephroureter-
ectomy with open bladder cuff resection. Laparoscopic nephrectomy
with open ureterectomy and bladder cuff resection was done in 3
patients. The mean age of the patients was 69.5 (39.9–84.3) years. In
5 cases the upper urinary tract tumors were multilocular in the renal
pelvis and the ureter, in 12 cases unilocular in the renal pelvis and in
12 cases unilocular in the ureter. The pathologic stage was
pTa,N0,M0,R0,G2 in 1 patient, pT1,N0,M0,R0,G1–2 in 9 patients,
pT2,N0,M0,R0,G2–3 in 11 patients, pT3,N0,M0,R0,G2–3 in 6
patients. Resection of the bladder cuff was histologically incomplete
(R1) (pT3,N0,M0,R1,G3) in 2 cases.
Tumor recurrence was detected by abdominal sonography, urine
cytology, cystoscopy and/or intravenous pyelography. Follow-up was
done by office urologists. For statistical analysis, cross tables with ¯2
test and the Pearson correlation were used.
Results
Mean follow-up was 3.37 (0.1–11.2) years. The 2 cases
with R1 status after nephroureterectomy had had histo-
logically incomplete resection of TCC at the bladder cuff.
One patient with pT3 status and positive margins at the
bladder cuff received adjuvant chemotherapy without
tumor recurrence. The other patient with pT3 R1 status
died 7 months after surgery aged 85 without evidence of
recurrence. 3/29 (10.3%) patients died due to tumor pro-
gression and 5 (17.2%) died of unrelated causes. 2/29
(6.9%) patients after removal of pT2–3,N0,M0,R0,G2–3
unilocular upper tract TCC developed hepatic and pul-
monary metastases or localized TCC of the contralateral
ureter without bladder TCC after 6 and 18 months,
respectively. Both patients received systemic palliative
chemotherapy and died due to tumor progression.
11/29 (37.9%) patients suffered TCC recurrence over-
all. In 9/29 (31.0%) patients bladder TCC was diagnosed
in a mean time of 2.5 (range 0.9–6.0) years after surgery.
Overall, 6/9 patients with bladder TCCs recurrence devel-
oped bladder TCC within the first 3 years after nephro-
ureterectomy. Only 1/9 patients had bladder TCC more
than 5 years after nephroureterectomy. While none of
these patients suffered from muscle-invasive bladder
TCC, 3/9 patients had a high-grade bladder TCC. Two
patients with high-grade bladder TCC underwent radical
cystectomy in a mean time of 1 year after nephroureterec-
tomy. In 1 case the bladder TCC was seen in combination
with systemic progression. Despite systemic chemothera-
py, the recurrent TCC led to death of disease 3.9 years
after primary surgery.
In our study, male patients had a significant higher risk
of bladder TCC recurrence (p ! 0.02). We found no corre-
lations between stage (p = 0.056), grade (p = 0.095) or
multifocality (p = 0.726) in the upper urinary tract and the
incidence of bladder TCC recurrence. 13/29 (44.8%) pa-
tients are alive without tumor recurrence with a mean fol-
low-up of 4.32 (range 0.49–11.2) years.
Discussion
TCC of the upper tract occurs in older patients [1, 8].
The mean age of our patients was 69.5 years and 16/29
(55.2%) patients in our series were over 70 years old.
Nephroureterectomy with a bladder cuff is the standard
treatment for upper tract TCC because of the multifocal
nature of this malignancy. An evaluation of the influence
of using an open versus an endoscopic technique for blad-
der cuff removal on the rate of bladder TCC recurrence
after nephroureterectomy in 145 patients showed no sig-
nificant difference in the recurrence rate [8]. In selected
cases with contraindications of nephrectomy, nephron-
sparing surgery is recommended for single, low-grade and
stage TCC in the distal ureter. The survival rates of
patients who underwent partial ureterectomy or complete
nephroureterectomy were equal for low-grade and stage
TCC [9].
In our series all patients were preoperatively free of
bladder TCC on cystoscopy. 9/29 (31.0%) of this selected
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group of patients later developed TCC recurrence in the
bladder. This is comparable to the data in the literature
which, however, include several series with patients in-
cluded with a previous history of bladder TCC [1, 6–8, 10,
11]. Therefore, our data with a selected group of patients
without a history of previous bladder TCC and without
concurrent bladder TCC give a reasonable indication of
the true risk of bladder TCC recurrence after surgery for
upper tract TCC.
In 6/9 (66.7%) of the patients with bladder TCC recur-
rence, the bladder tumor occurred within the first 3 years,
with a mean time of 2.5 years. Patients with high-grade
bladder TCC recurrence required radical cystectomy
within the first 12 months after nephroureterectomy.
Patients with systemic recurrence of TCC were detected
within the first 2 years.
Various possible risk factors for the development of
bladder TCC recurrence have been described in the litera-
ture. Independent factors for bladder TCC recurrence
seem to be multifocality of the upper tract TCC and
pathologic stage [7, 10]. Salvador-Bayarri et al. [8] de-
scribed a higher incidence of bladder recurrence after
high-grade upper tract TCC, while Koga et al. [11] in their
series described female sex, the administration of adju-
vant chemotherapy and incomplete distal ureterectomy
(R1) as risk factors for the bladder TCC recurrence after
nephroureterectomy for upper tract TCC. In contrast to
the literature, we found correlations between the male sex
and bladder TCC recurrence in our series. The stage (p =
0.056) and the grade (p = 0.095) of the upper tract TCC
correlated without statistical significance. This may possi-
bly be related to the high number of low-stage and low-
grade upper tract TCCs in our series and possibly also to
the lack of statistical power due to the small number of
patients with TCC recurrence in this highly selected
group.
Conclusions
Our data show a high incidence of bladder TCC recur-
rence after nephroureterectomy for TCC of the upper
tract of up to 6 years after primary surgery. Because of the
high incidence of bladder tumor recurrence appearing
within the first 3 years after surgery, a careful follow-up is
mandatory over at least this period.
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